帕金森病临床亚型的预后与神经病理相关性
该回顾性队列研究纳入111例尸检确诊的帕金森病患者,基于诊断时运动症状、快速眼动睡眠行为障碍、自主神经和认知功能严重程度分为轻度运动主导型、中间型和弥漫恶性型。弥漫恶性型疾病里程碑出现更早、生存期更短,调整后任何疾病里程碑风险比为10.90,死亡风险比为3.65。路易病理和阿尔茨海默病相关病理的分期在亚型间无差异,但进展速率不同,后者与死亡年龄相关。
要点
- 诊断时临床亚型可预估帕金森病病程和生存期。
- 弥漫恶性型患者疾病里程碑出现更早且死亡风险更高。
- 诊断年龄是唯一额外显著的死亡风险因素。
核心结论
- 帕金森病诊断时临床亚型可能预估疾病病程和生存期,有助于临床实践中的个体化预后和临床试验亚组分层。
- 神经病理的严重程度和进展速度是帕金森亚型的重要决定因素,未来亚型分类应纳入诊断年龄。
研究设计与样本
- 最终纳入111例患者(67例男性,60.4%),诊断时平均年龄62.5岁(标准差11.5)。
- 基于诊断时运动症状、快速眼动睡眠行为障碍、自主神经和认知功能严重程度,将患者分类为轻度运动主导型、中间型或弥漫恶性型。
主要发现
- 弥漫恶性型亚型疾病里程碑出现更早且生存期缩短。
- Cox回归显示弥漫恶性组任何疾病里程碑的调整风险比为10.90(95% CI 5.51-21.58,P < .001),死亡的调整风险比为3.65(95% CI 1.98-6.75,P < .001)。
- 诊断年龄是唯一额外具有统计学意义的变量(死亡调整风险比1.14,95% CI 1.11-1.17,P < .001)。
- 路易病理和阿尔茨海默病相关病理的分期在亚型间无差异,但进展速率不同,后者与死亡年龄相关。
临床怎么用
- 诊断时根据运动症状、快速眼动睡眠行为障碍、自主神经和认知功能严重程度进行临床亚型分类,可辅助预估疾病病程和生存期。
- 弥漫恶性型患者应更早关注疾病里程碑(反复跌倒、轮椅依赖、痴呆、养老院安置)和死亡风险。
- 诊断年龄应作为预后评估和未来亚型分类的重要考虑因素。
局限性
- 回顾性队列研究设计可能存在选择偏倚和信息偏倚。
- 样本来自单中心脑库,结果外推需谨慎。
- 未报告亚型分类的信度或效度验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Clinical subtyping of Parkinson disease at diagnosis is useful in estimating disease course and survival. Severity and rate of progression of neuropathologies are important determinants of clinical Parkinson subtypes. OBJECTIVE: To provide longitudinal clinical disease-course data and neuropathologic correlation for newly proposed Parkinson disease subtypes. DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study of consecutive patients with autopsy-confirmed Parkinson disease who were regularly seen throughout their disease course by hospital specialists in the United Kingdom and donated their brain at death to the Queen Square Brain Bank between January 2009 and December 2017. Patients with additional neuropathologic diagnoses, monogenic forms of parkinsonism, or insufficiently detailed clinical information were excluded. Based on severity of motor symptoms, rapid eye movement sleep behavior disorder, and autonomic and cognitive function at diagnosis, patients were classified adapting a subtyping classification into mild-motor predominant, intermediate, or diffuse malignant subtypes. MAIN OUTCOMES AND MEASURES: Time from diagnosis to disease milestones (recurrent falls, wheelchair dependence, dementia, and care home placement) and death were compared between subtypes, and their risk was estimated using Cox hazard regression models. Severity and distribution of Lewy pathology and Alzheimer disease-related pathology were assessed using staging systems. RESULTS: From a total of 146 patients, 111 patients were included (67 men [60.4%]; mean [SD] age at diagnosis, 62.5 [11.5] years). The diffuse malignant subtype had earlier development of milestones and reduced survival. Cox proportional hazard regression showed an increased adjusted risk of any disease milestone (hazard ratio, 10.90; 95% CI, 5.51-21.58; P < .001) and death (hazard ratio, 3.65; 95% CI, 1.98-6.75; P < .001) in the diffuse malignant group. Age at diagnosis was the only additional variable with statistical significance (adjusted hazard ratio for death, 1.14; 95% CI, 1.11-1.17; P <.001). Staging of Lewy pathology and Alzheimer disease-related pathology did not differ between subtypes, although they showed different rates of progression, and the latter was associated with age at death. CONCLUSIONS AND RELEVANCE: Parkinson clinical subtypes at diagnosis may estimate disease course and survival, which may be useful in providing a more accurate prognosis in individual patients in clinical practice and helping to stratify subgroups in clinical trials. Different severity and progression of neuropathologies are important determinants of Parkinson subtypes, and age at diagnosis should be included in future subtype classifications.
引用
- De Pablo-Fernández E, Lees AJ, Holton JL, et al. Prognosis and Neuropathologic Correlation of Clinical Subtypes of Parkinson Disease. JAMA Neurol. 2019. PMID: 30640364. doi:10.1001/jamaneurol.2018.4377
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。